Therefore, inflammation mediated by IL-6–Th17 pathway can probably drive the progress of irEC, so that addition of IL-6 blockers to tumor-bearing mice treated with anti–CTLA-4 reduces Th17, macrophages counts and tumor load, but promotes tumor shrinkage and increases survival rate of mice (37). Here, CTLA4 is linked to neoplasm.